What is HC Wainwright's Forecast for Cibus FY2026 Earnings?

Cibus logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright lowered its FY2026 Cibus EPS forecast to a loss of $1.18 per share from a loss of $1.13; the consensus estimate is a loss of $1.13.
  • Cibus reported a quarterly loss of $0.29 per share, missing the $0.20 consensus loss, while revenue of $0.80 million also fell short of expectations of $1.30 million.
  • Analyst opinions are mixed: one Buy, one Hold and one Sell, resulting in an average rating of Hold and an average price target of $9.
  • Five stocks we like better than Cibus.

Cibus, Inc. (NASDAQ:CBUS - Free Report) - Equities researchers at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for Cibus in a report issued on Friday, November 13th. HC Wainwright analyst A. Dayal now forecasts that the company will post earnings per share of ($1.18) for the year, down from their previous forecast of ($1.13). The consensus estimate for Cibus' current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for Cibus' Q4 2026 earnings at ($0.28) EPS, FY2027 earnings at ($1.10) EPS, FY2028 earnings at ($1.12) EPS and FY2029 earnings at ($0.53) EPS.

Cibus (NASDAQ:CBUS - Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.09). Cibus had a negative return on equity of 363.93% and a negative net margin of 2,131.38%. The business had revenue of $0.80 million during the quarter, compared to analysts' expectations of $1.30 million.

CBUS has been the topic of several other research reports. Wall Street Zen cut shares of Cibus from a "hold" rating to a "sell" rating in a report on Saturday, October 17th. Weiss Ratings restated a "sell (e+)" rating on shares of Cibus in a research note on Friday, September 25th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $9.00.

View Our Latest Analysis on CBUS

Cibus Price Performance

CBUS opened at $1.20 on Tuesday. The firm has a 50 day moving average price of $1.43 and a 200-day moving average price of $1.82. Cibus has a twelve month low of $1.02 and a twelve month high of $4.19.

Hedge Funds Weigh In On Cibus

Several institutional investors have recently made changes to their positions in CBUS. Dimensional Fund Advisors LP purchased a new position in shares of Cibus in the first quarter worth approximately $33,000. Nautilus Advisors LLC purchased a new stake in Cibus during the third quarter valued at approximately $35,000. Rockland Trust Co. purchased a new stake in Cibus during the second quarter valued at approximately $41,000. StoneX Group Inc. increased its holdings in Cibus by 115.9% during the third quarter. StoneX Group Inc. now owns 30,605 shares of the company's stock valued at $50,000 after buying an additional 16,430 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp bought a new position in Cibus in the first quarter worth approximately $66,000. Institutional investors own 33.81% of the company's stock.

Cibus Company Profile

(Get Free Report)

Cibus is an agricultural technology company that develops plant traits using gene-editing technologies. Its proprietary Rapid Trait Development System (RTDS) is designed to make precise changes to a plant's own genes, with the goal of developing useful crop characteristics without adding foreign DNA. The company's research and development focuses on traits for crops including canola, rice and wheat, such as herbicide tolerance and resistance to crop diseases. Cibus aims to bring these traits to market through seed and technology licensing arrangements with partners in the agricultural industry.

Read More

Earnings History and Estimates for Cibus (NASDAQ:CBUS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cibus Right Now?

Before you consider Cibus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cibus wasn't on the list.

While Cibus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines